Asymptomatic left ventricular noncompaction--implications for athletic participation

Michael E Pitzer1, Peter H Seidenberg, Matthew Silvis

  • 11Family Medicine, Virginia Commonwealth University, Richmond, VA; 2Penn State University Primary Care Sports Medicine Fellowship - State College, Orthopaedics and Rehabilitation, Family and Community Medicine, Penn State College of Medicine, Penn State University, State College, PA; and 3Penn State Primary Care Sports Medicine Fellowship, Departments of Family and Community Medicine and Orthopedics and Rehabilitation, Penn State Milton S. Hershey Medical Center, Hershey, PA.

Insights

Left ventricular noncompaction (LVNC) is a rare heart muscle condition. Research is needed to understand disease progression and outcomes in asymptomatic adults with LVNC.

Area of Science:

  • Cardiology
  • Cardiovascular Research
  • Myocardial Diseases

Background:

  • Left ventricular noncompaction (LVNC) is a rare cardiomyopathy characterized by abnormal left ventricular myocardial development.
  • Current understanding of LVNC primarily comes from symptomatic patients at referral centers, limiting knowledge of its natural history.
  • The progression and outcomes of incidentally discovered, asymptomatic LVNC in adults remain largely uncharacterized.

Observation:

  • Limited data exists on the long-term prognosis of individuals with asymptomatic left ventricular noncompaction.
  • There are no evidence-based guidelines for clinical surveillance or therapeutic interventions in this patient group.
  • The impact of LVNC on athletic eligibility is not well-defined, particularly in low-risk individuals.

Findings:

  • Disease progression and clinical outcomes for adult patients with incidentally found, asymptomatic LVNC are not established.
  • The lack of data prevents the development of evidence-based recommendations for follow-up and treatment.
  • Insufficient evidence currently supports restricting athletic participation in asymptomatic, low-risk individuals with LVNC.

Implications:

  • Further research is crucial to define the natural history and risk stratification of asymptomatic LVNC.
  • Establishing follow-up protocols and intervention criteria for asymptomatic LVNC is a clinical priority.
  • Clarifying the safety of athletic participation for low-risk individuals with LVNC requires more investigation.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
801
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
6.2K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
805
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
3.5K
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
1.3K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
721